期刊文献+

浸润性膀胱癌Bcl-2、Her-2表达与保存膀胱术后放化疗疗效的相关性研究 被引量:1

暂未订购
导出
摘要 根治性膀胱全切术是浸润性膀胱癌的标准治疗方式,而近年研究认为,一部分浸润性膀胱癌患者采用保存膀胱手术的综合治疗,在保留膀胱功能的同时可达到与膀胱全切术相似的生存率,长期生存患者的膀胱功能良好,为了筛选出可从保存膀胱术后放化疗中获益的患者,实现浸润性膀胱癌的个体化治疗,
出处 《中国癌症杂志》 CAS CSCD 2008年第11期870-872,共3页 China Oncology
基金 温州市科委课题(编号:Y2006A026)
  • 相关文献

参考文献13

  • 1Shipley WU, Zielman AL, Kaufman DS, et al. Selective bladder preservation by trimodality therapy for patients with muscularis propria-invasive bladder cancer and who are cystectomy candidates-the Massachusetts general hospital and Radiation Therapy Oncology Group experiences [ J ] . Semin Radiat Oneol, 2004, 15(1): 36-41
  • 2Vollmer RT, Humphrey PA, Swanson PE,et al. Invasion of the bladder by transitional cell carcinoma its relation to histologic grade and expression of P53, MIB-1, c-erb B-2, epidermal growth factor receptor, and Bcl-2 [ J ] . Cancer, 1998, 82(5): 715-723.
  • 3Hussain SA, Ganesan R, Hiller L, et al. Bcl-2 expression predicts survival in patients receiving synchronous chemoradiotherapy in advanced transitional cell carcinoma of the bladder [ J ].Oncol Rep, 2003, 10(3): 571-576.
  • 4Cooke PW, James ND, Ganesan R, et al. Bcl-2 expression identifies patients with advanced bladder cancer treated by radiotherapy who benefit from neoadjuvant chemotherapy [ J ] . BJU Int, 2000, 85(7): 829-835.
  • 5殷蔚伯,谷铣之主编.肿瘤放射治疗学[M].第3版.北京:中国协和医科大学出版社,2003:538-542、565.
  • 6Tsai YS, Tzai TS, Chow NH, et al. Does Her-2 immunoreactivity provide prognostic information in locally advanced urothelial carcinoma patients receiving adjuvant M-VEC chemotherapy? [ J ] . Urol Int, 2007, 79(1): 210- 216.
  • 7张世林,杨为民.HER-2原癌基因及其在膀胱癌中的研究进展[J].国外医学(泌尿系统分册),2004,24(3):354-357. 被引量:3
  • 8Rotterud R, Berner A, Holm R, el al. P53, p21 and mdm2 expression vs the response to radiotherapy in transitional cell carcinoma of the bladder [ J ] . Bju Int, 2001, 88(3): 202- 208.
  • 9Ribeiro JC, Barnetson AR, Fisher RJ, et al. Relationship between radiation response and P53 status in human bladder cancer cells [ J ] . Int J Radiat Biol, 1997, 72(1): 11-20.
  • 10Mothersill C, Malley K, Harney J, et al. Further investigation of the reponse of human uroepithelium to low doses of cobah- 60 gammar radiation [ J ]. Radiat Res, 1997, 147(2): 156- 165.

二级参考文献25

  • 1Droller MJ.Bladder cancer:state-of-the-art care.CA Cancer J Clin,1998,48,269~284
  • 2Jeffrey SR,Jonathan AF.HER-2/neu(C-erbB-2)gene and protein in breast cancer.Am J Clin Pthol,1999,112(sup),s53
  • 3Karunagaran D,Tzahar E,Beerli RR,et al.ErbB-2 is a common auxiliary subunit of NDF and EGF receptors:implications for breast cancer.EMBO J,1996,15,254~264
  • 4Yarden Y,Sliwkowski MX.Untangling the ErbB signalling network.Nat Rev Mol Cell Biol,2001,2,127~137
  • 5Joensuu H,Isola J,Lundin M,et al.Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer:a nationwide population-based study.Clin Cancer Res,2003,9,923~930
  • 6Hayes DF,Thor AD.c-erbB-2 in breast cancer:development of a clinically useful marker.Semin Oncol,2002,29,231~245
  • 7Paik S,Tan-chui E,Bryan J,et al.Successful quality assurance program for HER-2 testing in the NSABP trial for Herceptin.Breast Cancer Res Treat,2002,76(suppl 1),S31
  • 8Zhao J,Wu R,Au A,et al.Determination of HER2 gene amplification by chromogenic in situ hybridization(CISH) in archival breast carcinoma.Mod Pathol,2002,15,657~665
  • 9El-Ahmady O,El-Salahy E,Mahmoud M,et al.Multivariate analysis of bcl-2,apoptosis,P53 and HER-2/neu in breast cancer:a short-term follow-up.Anticancer Res,2002,22,2493~2499
  • 10Jensen B,Johansen J,Price P.High.Levels of Serum HER-2/neu and YKL-40 Independently Reflect Aggressiveness of Metastatic Breast Cancer.Clin Cancer Res,2003,9(12),4423~4434

共引文献7

同被引文献11

引证文献1

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部